AMARYL 4 MG
GLIMEPIRIDE : 4 MG · DIN 02245274 · SANOFI-AVENTIS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is AMARYL?
AMARYL 4 MG contains GLIMEPIRIDE : 4 MG. It is listed in the Health Canada Drug Product Database under DIN 02245274, held by SANOFI-AVENTIS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 07-Jun-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02245274 |
|---|---|
| Brand name | AMARYL |
| Generic / active ingredient | GLIMEPIRIDE : 4 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 4 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BB12 GLIMEPIRIDE |
| AHFS class | 68:20.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 07-Jun-2018 |
| Original market date | 2002-03-12 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A10BB12 GLIMEPIRIDE. 3 of 22 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SANDOZ GLIMEPIRIDE | 1 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02269589 |
| SANDOZ GLIMEPIRIDE | 2 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02269597 |
| SANDOZ GLIMEPIRIDE | 4 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02269619 |
| AMARYL | 1 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02245272 |
| AMARYL | 2 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02245273 |
| APO-GLIMEPIRIDE | 1 MG | TABLET | APOTEX INC | DORMANT | DIN 02295377 |
| APO-GLIMEPIRIDE | 2 MG | TABLET | APOTEX INC | DORMANT | DIN 02295385 |
| APO-GLIMEPIRIDE | 4 MG | TABLET | APOTEX INC | DORMANT | DIN 02295393 |
| CO GLIMEPIRIDE | 1 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED POST MARKET | DIN 02274248 |
| CO GLIMEPIRIDE | 2 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED POST MARKET | DIN 02274256 |
Who else supplies GLIMEPIRIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GLIMEPIRIDE appears in 325 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.